Dermatologic manifestation of hyperandrogenism: A retrospective chart review

SKINmed

Volumn 12, Issue 2, 2014, Pages 84-88

  Clark, Charlotte M ^a   Rudolph, Jennifer ^b   Gerber, Donald A ^c   Glick, Sharon ^d   Shalita, Alan R ^e   Lowenstein, Eve J ^d  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^b YALE NEW HAVEN HEALTH SYSTEM   (United States)

^c SUNY DOWNSTATE MEDICAL CENTER   (United States)

^d Downstate Health Sciences University   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACANTHOSIS NIGRICANS; ACNE VULGARIS; ADULT; ARTICLE; FEMALE; HIRSUTISM; HUMAN; HYPERANDROGENISM; OBESITY; OLIGOMENORRHEA; OVARY POLYCYSTIC DISEASE; RETROSPECTIVE STUDY; SKIN DISEASE;

ACANTHOSIS NIGRICANS; ACNE VULGARIS; ADULT; FEMALE; HIRSUTISM; HUMANS; HYPERANDROGENISM; OLIGOMENORRHEA; OVERWEIGHT; POLYCYSTIC OVARY SYNDROME; RETROSPECTIVE STUDIES; SKIN DISEASES;

EID: 84904391430     PISSN: 15409740     EISSN: 17517125     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Amato P, Simpson JL. The genetics of polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2004;18:707–718.
2. Azziz R, Carmina E, Dewailly D, et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. J Clin Endocrinol Metab. 2006;91:4237–4245.
3. Balen AH, Laven JS, Tan SL, Dewailly D. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update. 2003;9:505–514.
4. Balen A, Michelmore K. What is polycystic ovary syndrome? Are national views important? Hum Reprod. 2002;17:2219–2227.
5. Banaszewska B, Spaczynski RZ, Pelesz M, Pawelczyk L. Incidence of elevated LH/FSH ratio in polycystic ovary syndrome women with normo-and hyperinsulinemia. Rocz Akad Med Bialymst. 2003;48:131–134.
6. Carmina E, Rosato F, Janni A, Rizzo M, Longo RA. Extensive clinical experience: Relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. J Clin Endocrinol Metab. 2006;91:2–6.
7. Cordain L, Eades MR, Eades MD. Hyperinsulinemic diseases of civilization: more than just syndrome X. Comp Biochem Physiol A Mol Integr Physiol. 2003;136:95–112.
8. Cupisti S, Kajaia N, Dittrich R, et al. Body mass index and ovarian function are associated with endocrine and metabolic abnormalities in women with hyperandrogenic syndrome. Eur J Endocrinol. 2008;158:711–719.
9. Diamanti-Kandarakis E, Baillargeon JP, Iuorno MJ, Jakubowicz DJ, Nestler JE. A modern medical quandary: Polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. J Clin Endorinol Metab. 2003;88:1927–1932.
10. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005;352:1223–1236.
11. Franks S. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: in defense of the Rotterdam criteria. J Clin Endocrinol Metab. 2006;91:786–789.
12. Hart R, Hickey M, Franks S. Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2004;18:671–683.
13. Lee AT, Zane LT. Dermatologic manifestations of polycystic ovary syndrome. Am J Clin Dermatol. 2007;8:201–219.
14. Legro RS. A 27-year-old woman with a diagnosis of polycystic ovary syndrome. JAMA. 2007;297:509–519.
15. Lowenstein EJ. Diagnosis and management of the dermatologic manifestations of the polycystic ovary syndrome. Dermatol Ther. 2006;19:210–223.
16. Randall VA. Androgens and hair growth. Dermatol Ther. 2008;21:314–328.
17. Rosenfield RL. What every physician should know about polycystic ovary syndrome. Dermatol Ther. 2008;21:354–361.
18. Schmidt JB. Other antiandrogens. Dermatology (Basel, Switzerland). 1998;196:153–157.
19. Somani N, Harrison S, Bergfeld WF. The clinical evaluation of hirsutism. Dermatol Ther. 2008;21:376–391.
20. Stein I, Leventhal M. Amenorrhoea associated with bilateral polycystic ovaries. Am J Obstet Gynecol. 1935;29:181–185.
21. Talbott E, Clerici A, Berga SL, et al. Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. J Clin Epidemiol. 1998;51:415–422.
22. Yildiz BO, Yarali H, Oguz H, Bayraktar M. Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88:2031–2036.
23. Williamson K, Gunn AJ, Johnson N, Milsom SR. The impact of ethnicity on the presentation of polycystic ovarian syndrome. Aust NZ J Obstet Gynaecol. 2001;41:202–206.
24. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84:3666–3672.
25. Wijeyaratne CN, Balen AH, Barth JH, Belchetz PE. Clinical manifestations and insulin resistance (IR) in polycystic ovary syndrome (PCOS) among South Asians and Caucasians: is there a difference? Clin Endocrinol (Oxf). 2002;57:343–350.
26. Van Santbrink EJ, Hop WC, Fauser BC. Classification of normogonadotropic infertility: polycystic ovaries diagnosed by ultrasound versus endocrine characteristics of polycystic ovary syndrome. Fertil Steril. 1997;67:452–458.